PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Charbonnel
Bernard
B
Diabetes and Endocrinology Department, Institut du Thorax, University of Nantes, 44000 Nantes, France. Bernard.Charbonnel@univ-nantes.fr
D000476:Alkanesulfonates / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010080:Oxazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D047493:PPAR alpha / Q000819:agonists* / Q000502:physiology; D047495:PPAR gamma / Q000819:agonists* / Q000502:physiology; D010666:Phenylpropionates / Q000009:adverse effects; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use
D000476:Alkanesulfonates; D007004:Hypoglycemic Agents; D010080:Oxazoles; D047493:PPAR alpha; D047495:PPAR gamma; D010666:Phenylpropionates; D013876:Thiophenes; C542437:aleglitazar; C501413:tesaglitazar; D005998:Glycine; C500085:muraglitazar